NeoGenomics - NEO Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NEO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NEO, but not buy additional shares or sell existing shares.
View NEO analyst ratings or view top-rated stocks.

11 analysts have issued twelve-month price targets for NeoGenomics' stock. Their NEO share price forecasts range from $16.00 to $30.00. On average, they anticipate the company's share price to reach $20.08 in the next year. This suggests a possible upside of 140.7% from the stock's current price.
View analysts price targets for NEO or view top-rated stocks among Wall Street analysts.

NeoGenomics' stock was trading at $34.12 at the beginning of the year. Since then, NEO stock has decreased by 75.6% and is now trading at $8.34.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NEO earnings forecast.

NeoGenomics, Inc. (NASDAQ:NEO) released its earnings results on Tuesday, August, 9th. The medical research company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.06. The medical research company earned $125 million during the quarter, compared to the consensus estimate of $123.26 million. NeoGenomics had a negative trailing twelve-month return on equity of 8.53% and a negative net margin of 30.00%. NeoGenomics's quarterly revenue was up 2.5% compared to the same quarter last year. During the same period last year, the business earned ($0.04) earnings per share.

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics' stock is owned by many different institutional and retail investors. Top institutional investors include Brown Advisory Inc. (4.43%), Brown Advisory Inc. (4.46%), State Street Corp (3.26%), Assenagon Asset Management S.A. (2.89%), First Light Asset Management LLC (2.18%) and Federated Hermes Inc. (2.13%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends.

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NEO stock can currently be purchased for approximately $8.34.

NeoGenomics (NASDAQ:NEO) has a market capitalization of $1.05 billion and generates $484.33 million in revenue each year. The medical research company earns $-8,350,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

The company employs 2,000 workers across the globe.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237.